$RPRX insider trading
Over the last 12 months, Royalty Pharma insiders reported no purchases and 36 sales totaling $84.9M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $84.9M 36 events
- Events · 12m
- 36 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 100,000 | $59.97 | $6.0M | -21.3% | plan · indirect |
| Aug 13, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 11,002 | $58.68 | $646K | -100% | plan · 2 tranches · indirect |
| Jul 1, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 9,099 | $55.88 | $508K | -100% | plan |
| Jun 30, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 30,000 | $56.46 | $1.7M | -42.9% | plan · 2 tranches |
| Jun 30, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 100,000 | $56.52 | $5.7M | -17.9% | plan · 2 tranches · indirect |
| Jun 24, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 9,098 | $55.18 | $502K | -50% | plan |
| Jun 23, 2026 | Hite ChristopherEVP & Chairman, Partnering · O | ▼ Sale | 150,000 | $54.4 | $8.2M | -21.1% | plan · 2 tranches · indirect |
| May 26, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 64,399 | $53.98 | $3.5M | -100% | plan · indirect |
| Apr 28, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 34,791 | $49.78 | $1.7M | -46.4% | plan · 2 tranches · indirect |
| Apr 1, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 34,791 | $48.33 | $1.7M | -51.4% | plan · 2 tranches · indirect |
| Mar 23, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 34,791 | $45.53 | $1.6M | -44.2% | plan · 2 tranches · indirect |
| Mar 2, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 34,791 | $46.78 | $1.6M | -43.2% | plan · 4 tranches · indirect |
| Feb 23, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 34,791 | $45.32 | $1.6M | -42.2% | plan · 2 tranches · indirect |
| Feb 4, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 243,541 | $42.54 | $10.4M | -91.4% | plan · 6 tranches · indirect |
| Jan 30, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $41.09 | $822K | -100% | plan · indirect |
| Jan 23, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $40.26 | $805K | -50% | plan · indirect |
| Jan 20, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,582 | $39.35 | $2.7M | -65.9% | plan · 2 tranches · indirect |
| Jan 16, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $39.52 | $790K | -33.3% | plan · indirect |
| Jan 9, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $40.78 | $816K | -25% | plan · indirect |
| Jan 2, 2026 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $38.48 | $770K | -20% | plan · indirect |
| Jan 2, 2026 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,582 | $38.42 | $2.7M | -63.6% | plan · 2 tranches · indirect |
| Dec 26, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $39.32 | $786K | -16.7% | plan · indirect |
| Dec 19, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $38.38 | $768K | -14.3% | plan · indirect |
| Dec 18, 2025 | Lloyd George W.EVP, Investments & CLO · O | ▼ Sale | 110,000 | $38.55 | $4.2M | -100% | plan · 2 tranches · indirect |
| Dec 16, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 20,000 | $38.32 | $766K | -12.5% | plan · indirect |
| Dec 15, 2025 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,582 | $38.36 | $2.7M | -61.5% | plan · 2 tranches · indirect |
| Dec 5, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 18,242 | $39.15 | $714K | -71.1% | plan |
| Dec 5, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 23,334 | $39.15 | $914K | -12.7% | plan · indirect |
| Dec 3, 2025 | Lloyd George W.EVP, Investments & CLO · O | ▼ Sale | 110,000 | $39.77 | $4.4M | -50% | plan · indirect |
| Dec 1, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 18,242 | $39.9 | $728K | -41.6% | plan |
| Dec 1, 2025 | Urist MarshallEVP, Research & Investments · O | ▼ Sale | 23,333 | $39.93 | $932K | -11.3% | plan · indirect |
| Dec 1, 2025 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,582 | $39.87 | $2.8M | -59.6% | plan · 2 tranches · indirect |
| Nov 24, 2025 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,582 | $38.55 | $2.7M | -57.7% | plan · 4 tranches · indirect |
| Nov 19, 2025 | Lloyd George W.EVP, Investments & CLO · O | ▼ Sale | 3,000 | $38.34 | $115K | -100% | plan · 2 tranches |
| Nov 19, 2025 | Lloyd George W.EVP, Investments & CLO · O | ▼ Sale | 132,426 | $38.34 | $5.1M | -100% | plan · 6 tranches · indirect |
| Nov 17, 2025 | Coyne Terrance P.EVP & CFO · O | ▼ Sale | 69,594 | $39.3 | $2.7M | -56% | plan · 2 tranches · indirect |
| Aug 11, 2025 | Norden GregoryD | ▼ Sale | 33,500 | $36.23 | $1.2M | -14.7% | — |
Every $RPRX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Royalty Pharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RPRX feed.